Search Thermo Fisher Scientific
Oncomine BCR IGH Assays for Hemato-Oncology Research
Simple clonality assessment. Sensitive rare clone detection. Accurate somatic hypermutation analysis.
B-cell lymphomas and leukemias originate from the malignant transformation and proliferation of one or a small number of B cells. Since each B cell expresses distinct B-cell receptors (BCRs) on its surface, potential malignant clones of interest can be identified and measured by the unique BCR sequences from the original cell. These B-cell transformations are an important focus area for ongoing translational and clinical research.
Today, high-throughput sequencing of the BCR repertoire is increasingly being adopted to advance hemato-oncology research. Next-generation sequencing (NGS) offers significant advantages over traditional approaches by offering ultra-high sensitivity, lower limits of detection (LOD), and greater flexibility to multiplex.
The Ion Torrent Oncomine BCR IGH-LR (long read) and Oncomine BCR IGH-SR (short read) assays are a pair of robust and sensitive NGS-based assays that make it easier for hemato-oncology labs to assess B-cell clonality, measure somatic hypermutation (SHM), and detect rare B-cell clones of interest for measurable residual disease (MRD) research.
Oncomine BCR IGH LR Assay
Simple clonality & accurate somatic hypermutation (SHM) assessment
The Oncomine BCR IGH LR Assay uses long-read sequencing (~400 bp) to assess simple clonality and quantify somatic hypermutation in CDRs 1-3 of the IGHV gene—all from a single library preparation.
Key features:
- Simple & intuitive clonality assessment made possible by the unique interactive visualizations and automated clonal lineage analysis features of the informatics software
- Accurately measure the level of SHM in the IGHV genes with the ultralow substitution error rate of the Ion Torrent platform and the automated reporting built into the informatics software
- Accelerate time to answers with a 48-hour sample-to-results turnaround
- Gain efficiencies with the flexibility to multiplex with minimal sample input (as low as 25 ng) from a variety of common hematology sample types
Oncomine BCR IGH SR Assay
Sensitive rare clone detection for MRD research
The Oncomine BCR IGH SR Assay uses short-read sequencing to enable the detection of low-frequency B-cell clones in the sample. Compared to other methods, deep sequencing offers higher sensitivity and exceptionally low limit of detection.
Key features:
- Confidently detect rare B-cell clones through the unique CDR3 sequence with high sensitivity and ultra-low limit of detection (LOD) down to 10-6
- Easily measure and compare the frequency of potential malignant clones of interest for MRD research
- Accelerate time to answers with a 48-hour sample-to-results turnaround
- Choose from multiple chips and sample types to fit your unique sample batching needs, desired LOD, and throughput requirements
New hematological research insights. Same great Oncomine benefits.
We’ve made it easy for labs to implement and scale up with Oncomine solutions. As with the Oncomine TCR assays, the Oncomine BCR assays come with the same familiar end-to-end workflow that includes the bioinformatics and the unparalleled service and support you’ve come to expect from us.
From sample to insights in 48 hours
The Oncomine BCR IGH assays can be run on the Ion GeneStudio S5 systems. The LR assay is compatible with RNA input from a variety of common hematological sample types. The SR assay is compatible with both RNA and DNA from FFPE and hematological sample types. The entire workflow from library preparation to analysis of samples can be accomplished in 48 hours.
Click image to enlarge
仅供研究使用，不可应用于诊断程序。